RSS

X4 Pharmaceuticals

Clinical stage biopharmaceutical company, X4 Pharmaceuticals, has secured $27 million in series B funding that will be used to advance its two lead drug candidates in clinical efficacy studies in immune-oncology and a pivotal study in a rare disease. more

News